Skip to main content

Table 4 Patient characteristics of the MDS/low blast count AML cohort subjected to methylation analyses

From: Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients

Number of patients 62
Age (years; median and range) 70.5 (20–83)
 Male 40
 Female 22
FAB subtype  
 RA 17
 RAEB 35
 RAEB-t 5
IPSS risk category  
 Low 5
 Intermediate I 17
 Intermediate II 30
 High 10
 Del(7q) or -7 (%) 11 (18)
  1. CMML chronic myelomonocytic leukemia, IPSS International Prognostic Scoring System, RA refractory anemia, RAEB refractory anemia with blast excess, RAEB-t refractory anemia with blast excess in transformation (i.e., acute myeloid leukemia according to the World Health Organization classification), RARS refractory anemia with ring sideroblasts